The increased adverse events of epiglottic edema, epiglottis, pneumopericardium, upper airway obstruction, eosinophilic oesophagitis, edema mucosal, edema of the mouth, tracheal edema, palatal edema, and allergic edema associated with ACE inhibitors compared to beta blockers suggests that a thorough investigation of all 10 million plus adverse event reports is necessary, to triangulate any drug-induced side effects that also appear as comorbidities from the emerging evidence of COVID-19 mortality. Here, ACE is linked to COVID-19.